AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Phathom Pharmaceuticals, Inc. Director's Dealing 2020

Jul 2, 2020

32407_dirs_2020-07-02_a2281865-352b-43b8-b5c2-c6f6fee7144b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2020-07-01

Reporting Person: Nabulsi Azmi (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-01	Stock Option (Right to Buy)	$32.20	A	70000	Acquired	2030-06-30	Common Stock (70000)	Direct

Footnotes

F1: The stock option will vest with respect to 25% of the shares of common stock on July 1, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.